The law firm Schall announces that it

LOS ANGELES, June 6, 2024 (GLOBE NEWSWIRE) — The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims of violations of the securities laws on behalf of investors in Biomea Fusion, Inc. (“Biomea” or “the Company”) (NASDAQ: BMEA).

According to the complaint, the company made false and misleading statements to the market. Biomea issued a press release on June 6, 2024, announcing that it “has received notice from the U.S. Food and Drug Administration (FDA) that Biomea’s ongoing Phase I/II clinical trials of its investigational covalent menin inhibitor BMF-219 in type 2 and type 1 diabetes (COVALENT-111 and COVALENT-112) have been placed on full hold.” On the news, Biomea’s shares fell nearly 59% in after-hours trading that same day.

If you are a shareholder who has suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335 to discuss your rights free of charge. You may also contact us through the firm’s website at www.schallfirm.com or by email at [email protected].

The Schall Law Firm represents investors throughout the world and specializes in securities class action litigation and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under applicable laws and professional rules.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.
310-301-3335
[email protected]

www.schallfirm.com